NCT02857270View on ClinicalTrials.gov

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 29, 2016

Primary Completion Date

February 10, 2021

Study Completion Date

October 24, 2022

Conditions
Advanced CancerMetastatic MelanomaMetastatic Non-small Cell Lung CancerColorectal Cancer
Interventions
DRUG

LY3214996

Administered orally

DRUG

Midazolam

Administered orally

DRUG

Abemaciclib

Administered orally

DRUG

Nab-paclitaxel

Administered IV

DRUG

Gemcitabine

Administered IV

DRUG

Encorafenib

Administered orally

DRUG

Cetuximab

Administered IV

Trial Locations (13)

2010

St Vincent's Hospital, Sydney

6009

Linear Clinical Research Ltd, Nedlands

20007

Georgetown University Medical Center, Washington D.C.

34232

Florida Cancer Specialists, Sarasota

37203

Sarah Cannon Cancer Center, Nashville

Tennessee Oncology PLLC, Nashville

77030

University of Texas MD Anderson Cancer Center, Houston

94805

Gustave Roussy, Villejuif

02114

Massachusetts General Hospital, Boston

03756-0001

Dartmouth Hitchcock Medical Center, Lebanon

15232-1305

UPMC Hillman Cancer Center, Pittsburgh

411-8777

Shizuoka Cancer Center, Sunto-Gun

104-0045

National Cancer Center Hospital, Chuo-ku

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02857270 - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Biotech Hunter | Biotech Hunter